Patents Represented by Attorney, Agent or Law Firm Ivor R. Elrifi, Esq.
  • Patent number: 6649184
    Abstract: The invention provides a method for delivering biologically active molecules to the eye by implanting biocompatible capsules containing a cellular source of the biologically active molecule. Also provided is a method of treating ophthalmic diseases using biocompatible capsules.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: November 18, 2003
    Assignee: Neurotech S.A.
    Inventors: Joseph P. Hammang, E. Edward Baetge, William G. Tsiarias, Peter D. Spear
  • Patent number: 6638501
    Abstract: Multipotent neural stem cell (MNSC) progeny are transplanted into a recipient wherein they augment host tissue. The stem cells have a universal lineage potential and are capable of producing progeny that, in response to appropriate environmental signals, can differentiate into a variety of differentiated cell types, and not just neural lineages. MNSCs can be proliferated ex vivo to provide an unlimited supply of stem cells and stem cell progeny which give rise to the differentiated cell types of various tissues. The stem cells are readily amenable to genetic modification, if desired. They also have the advantage that they can be obtained from autologous adult human tissue and thus overcome prior art problems of transplant rejections.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 28, 2003
    Assignee: Neurospheres Holdings Ltd.
    Inventors: Christopher R. Bjornson, Rod L. Rietze, Brent A. Reynolds, Angelo L. Vescovi
  • Patent number: 6639668
    Abstract: The present invention is directed to asynchronous scanning devices and methods of using asynchronous scanning to acquire fluorescence data from a sample, such as biological tissue, to facilitate diagnosis of the presence or absence of disease or other abnormality in the sample. The present invention is useful for biomedical diagnostics, chemical analysis or other evaluation of the target sample.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: October 28, 2003
    Assignee: Argose, Inc.
    Inventor: Pierre Trepagnier
  • Patent number: 6638717
    Abstract: The present invention relates to a highly efficient, high-throughput method for the identification and elimination of redundancy in a population of nucleic acid molecules using microarrays. This method involves a reiterative subtraction protocol that creates a library that becomes more biased toward unknown genes with each successive round. The removal of repetitive and previously characterized nucleic acids from the library allows the identification of low-abundance mRNA from sources of interest and enhances the rate of novel gene discovery. The present invention is also useful for the removal of contaminating nucleic acids from cloning libraries.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: October 28, 2003
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Steven Perrin, Kathy Call, Timothy Connolly
  • Patent number: 6634837
    Abstract: A polycrystalline tungsten carbide ceramic cutting insert with chip control is disclosed for high speed machining.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: October 21, 2003
    Assignee: Cerbide Corporation
    Inventor: Linwood Anderson
  • Patent number: 6632604
    Abstract: The present invention relates to nucleic acid sequences which comprise all or part of a nucleic acid sequence of a CIITA gene. These sequences can comprise a sequence which exhibits a transcriptional promoter activity, which activity is, in particular, specifically expressed in one cell type. The sequences can also comprise a coding sequence. Therapeutic and diagnostic applications, in particular relating to disorders in which it is desirable to act on the level at which genes which encode the class II molecules of the major histocompatibility complex (MHC) are expressed.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: October 14, 2003
    Assignee: Novimmune SA
    Inventor: Bernard Mach
  • Patent number: 6630306
    Abstract: Polynucleotides having allosteric properties that modify a function or configuration of the polynucleotide with a chemical effector and/or physical signal are employed primarily as biosensors and/or enzymes for diagostic and catalytic purposes. In some preferred embodiments, the polynucleotides are DNA enzymes that are used in solution/suspension or attached to a solid support as biosensors to detect the presence or absence of a compound, its concentration, or physical change in a sample by observation of self-catalysis. Chemical effectors include organic compounds such as amino acids, amino acid derivatives, peptides, nucleosides, nucleotides, steroids, and mixtures of these with each other and with metal ions, cellular metabolites or blood components obtained from biological samples, steroids, pharmaceuticals, pesticides, herbicides, food toxins, and the like. Physical signals include radiation, temperature changes, and combinations thereof.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 7, 2003
    Assignee: Yale University
    Inventor: Ronald R. Breaker
  • Patent number: 6627422
    Abstract: A device is provided containing cells or tissue distributed on a filamentous cell-supporting matrix which is encapsulated by a semi-permeable membrane which can be immunoisolatory. The matrix may be formed of a plurality of monofilaments twisted into yarn that is in non-woven strands, or of the monofilaments or yarn woven into a mesh. Configurations of the matrix include a hollow cylinder, tube, solid cylinder or cord. A coating of extracellular matrix molecules may be on the matrix, or the matrix may be treated with plasma irradiation to enhance cell adhesion. The device can be made by inserting the matrix in a hollow membrane tube, injecting cells or tissue into the tube and sealing ends of the tube. The device is particularly useful for implantation into a mammalian host to provide therapy resulting from a biologically active molecule produced by the cells and tissue.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: September 30, 2003
    Assignee: Neurotech S.A.
    Inventors: Rebecca Li, David Rhein
  • Patent number: 6620617
    Abstract: A means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed. The gene, under control of an appropriate promoter for expression in a particular cell type, is encapsulated or dispersed with a biocompatible, preferably biodegradable polymeric matrix, where the gene is able to diffuse out of the matrix over an extended period of time, for example, a period of three to twelve months or longer. The matrix is preferably in the form of a microparticle such as a microsphere (where the gene is dispersed throughout a solid polymeric matrix) or microcapsule (gene is stored in the core of a polymeric shell), a film, an implant, or a coating on a device such as a stent. The size and composition of the polymeric device is selected to result in favorable release kinetics in tissue.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 16, 2003
    Assignee: Brown University Research Foundation
    Inventors: Edith Mathiowitz, Yong Shik Jong, Kim Boekelheide
  • Patent number: 6612988
    Abstract: The invention provides a method of delivering ultrasound signals. The method includes providing an image of at least a portion of a subject intended to receive ultrasound signals between sources of the ultrasound signals and a desired region of the subject for receiving focused ultrasound signals, identifying, from the image, physical characteristics of different layers of material between the sources and the desired region, and determining at least one of phase corrections and amplitude corrections for the sources depending on respective thicknesses of portions of each of the layers disposed between each source and the desired region.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: September 2, 2003
    Assignees: Brigham and Women's Hospital, Inc., InSightec - Image Guided Treatment Ltd.
    Inventors: Dov Maor, Javier Grinfeld, Kullervo Hynynen
  • Patent number: 6597932
    Abstract: An instrument for evaluating fluorescence of a heterogeneous tissue includes means for exciting a two-dimensional portion of the tissue surface with excitation radiation at a plurality of excitation wavelengths, means for collecting emission radiation from the two-dimensional portion of the tissue surface simultaneously with excitation of the portion, and means for forming a two-dimensional excitation-emission map of the excitation radiation and the simultaneously collected emission radiation and spatially averaging the excitation and emission radiation.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: July 22, 2003
    Assignee: Argose, Inc.
    Inventors: Wei Dong Tian, Pierre Trepagnier
  • Patent number: 6548058
    Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagenic or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated from blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: April 15, 2003
    Assignee: Epitech, S.A.
    Inventors: Thomas Hunziker, Alain Limat
  • Patent number: 6521412
    Abstract: The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: February 18, 2003
    Assignee: CuraGen Corporation
    Inventors: Meijia Yang, Krishnan Nandabalan, Vincent Peter Schulz
  • Patent number: 6506891
    Abstract: This invention provides cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by the host immune system. The invention also provides methods of using such cells, and capsules for delivery of biologically active molecules to a patient.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: January 14, 2003
    Assignee: Neurotech S.A.
    Inventors: Weng Tao, Shou Wong, William F. Hickey, Joseph P. Hammang, E. Edward Baetge
  • Patent number: 6497872
    Abstract: The invention provides methods of transplanting multipotent neural stem cell progeny to a host by obtaining a population of cells derived from mammalian neural tissue containing at least one multipotent CNS multipotent neural stem cell; culturing the neural stem cell in a culture medium containing one or more growth factors which induce multipotent neural stem cell proliferation; inducing proliferation of the multipotent neural stem cell to produce neural stem cell progeny which includes multipotent neural stem cell progeny cells; and transplanting the multipotent neural stem cell progeny to the host.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 24, 2002
    Assignee: NeuroSpheres Holdings Ltd.
    Inventors: Samuel Weiss, Brent Reynolds, Joseph P. Hammang, E. Edward Baetge
  • Patent number: 6498018
    Abstract: The invention provides a method for determining the effect of a biological agent comprising contacting a cell culture with a biological agent. The cell culture of the invention contains a culture medium containing one or more preselected growth factors effective for inducing multipotent central nervous system (CNS) neural stem cell proliferation. The cell culture also contains, suspended in the culture medium, human multipotent CNS neural stem cells that are derived from primary CNS neural tissue that have a doubling rate faster than 30 days.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: December 24, 2002
    Assignee: Cytotherapeutics, Inc.
    Inventor: Melissa Carpenter
  • Patent number: 6495364
    Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: December 17, 2002
    Assignee: Neurotech, S.A.
    Inventors: Joseph P. Hammang, Albee Messing
  • Patent number: 6486299
    Abstract: Common human diseases like diabetes and hypertension have been demonstrated to possess an associated genetic component composed of numerous underlying genetic defects. Traditional positional cloning of genes which possess the mutations responsible for complex disease has been hindered by both the low statistical power each locus may afford, and by the technically-laborious nature of the positional cloning methodologies. Disclosed herein is a methodology for the rapid identification of the genes responsible for quantitative trait loci (QTL) comprised of comprehensive gene expression analysis in organs relevant to disease in combination with the positional mapping of known QTL, so as to quantitatively identify candidate genes. This aforementioned methodology was applied to a total of five tissues/organs derived from the spontaneously hypertensive rat (SHR), the stroke-prone variant of the SHR (SHR-SP) and control Wistar Kyoto rats (WKY).
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: November 26, 2002
    Assignee: CuraGen Corporation
    Inventor: Richard A. Shimkets
  • Patent number: 6468794
    Abstract: Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 22, 2002
    Assignee: StemCells, Inc.
    Inventors: Nobuko Uchida, David W. Buck, Irving Weissman
  • Patent number: 6448239
    Abstract: This invention provides a novel class of substituted macrocyclic metallic complexes. The complexes are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: September 10, 2002
    Assignee: Trustees of Princeton University
    Inventors: John T. Groves, Suzanne M. Moeller